Company Tibet Duo Rui Pharmaceutical Co., Ltd.

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 2026-09-30			5-day change	1st Jan Change
63.17 ^CNY	-1.33%		-6.08%	+5.87%

09-28	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-20	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI

Business description: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Number of employees: 461

Sales by Activity: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Preparations	-	298M	235M	187M	55.36M
Active Pharmaceutical Ingredient (api)	-	-	-	10.32M	49.74M
Intermediate	-	103M	99.61M	38M	38.96M
Others	64.26M	-	-	5.51M	10.11M
Sodium Acetate Ringer's Injection	465M	-	-	-	-

See all business segments

Geographical breakdown of sales: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	530M	401M	334M	241M	154M

See all geographic segments

Executive Committee: Tibet Duo Rui Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	2018-11-30
Chao Li DFI	Director of Finance/CFO	47	2017-04-30
Fen Jin DFI	Director of Finance/CFO	46	2017-11-30
Ying Liu IRC	Investor Relations Contact	39	-
Bo Ao PRN	Corporate Officer/Principal	40	2022-03-22

See TIBET DUO RUI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	2017-11-30
Shao Zhong Zhang BRD	Director/Board Member	70	2020-02-20
Qin Deng BRD	Director/Board Member	58	2020-02-20
Ying Fei Liu BRD	Director/Board Member	48	2020-02-20
Fei Qi BRD	Director/Board Member	49	2020-02-20
Fen Jin BRD	Director/Board Member	46	2022-04-14
Yun Guo Wang BRD	Director/Board Member	54	2022-04-14

Composition of the Board of Directors

Shareholders: Tibet Duo Rui Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
China Asset Management Co., Ltd. 0.0394 %	10,800	0.0394 %	92 895 ¥
Orient Fund Management Co., Ltd. 0.0263 %	7,200	0.0263 %	61 930 ¥
Hongde Fund Management Co., Ltd. 0.005834 %	1,600	0.005834 %	13 762 ¥
CCB Principal Asset Management Co., Ltd. 0.001094 %	300	0.001094 %	2 580 ¥
Cinda Fund Management Co. Ltd. 0.000729 %	200	0.000729 %	1 720 ¥

List of TIBET DUO RUI PHARMACEUTICAL CO., LTD. shareholders

Company details: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co., Ltd.

3/F, Building 1, Biomedical Park

854000, Changdu

http://www.duoruiyy.com

address Tibet Duo Rui Pharmaceutical Co., Ltd.(301075)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-1.33%	-6.08%	+57.61%	+127.97%	763M
ELI LILLY AND COMPANY	-2.33%	-1.12%	+59.27%	+115.42%	1,056B
JOHNSON & JOHNSON	-1.06%	-1.65%	+45.77%	+69.98%	645B
ABBVIE INC.	-0.65%	-1.36%	+17.22%	+75.49%	465B
MERCK & CO., INC.	-2.66%	-3.71%	+84.92%	+41.15%	368B
ROCHE HOLDING AG	-0.06%	-4.12%	+36.31%	+39.39%	335B
NOVARTIS AG	-0.79%	+3.01%	+21.11%	+27.79%	275B
ASTRAZENECA PLC	-1.19%	-3.09%	+10.75%	+10.61%	255B
AMGEN INC.	-0.50%	+2.75%	+53.85%	+56.84%	229B
GILEAD SCIENCES, INC.	-1.47%	-2.37%	+32.35%	+98.89%	188B
Average	-0.66%	-0.34%	+41.92%	+66.35%	381.65B
Weighted average by Cap.	-0.33%	+0.30%	+44.68%	+71.40%